Abstract
ACAA1 is highly expressed in TNBC, serving as a potential therapeutic target in ACAA1-high tumors and a predictive biomarker of resistance to CDK4/6 inhibitors for RB1-proficient patients.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have